Spots Global Cancer Trial Database for adverse drug event
Every month we try and update this database with for adverse drug event cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients | NCT02324803 | Self Efficacy Adverse Drug Ev... Carcinoma, Rena... | pazopanib | 18 Years - | Southern China Urology Cancer Consortium | |
| Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia | NCT04770922 | Acute Lymphobla... Adverse Drug Ev... | - 21 Years | Cipherome, Inc. | ||
| Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer | NCT06152471 | Early-stage Bre... Diarrhea Adverse Drug Ev... | SPC-flakes Salovum Placebo | 18 Years - | Uppsala University Hospital | |
| Rheumatologic Adverse Events and Cancer Immunotherapy | NCT04791150 | Oncology Autoimmunity Arthritis Adverse Drug Ev... | Fill in a form | 18 Years - | Poitiers University Hospital | |
| Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer | NCT01080547 | Length of Stay Complications Adverse Drug Ev... Quality of Life Hospital Costs | Laparoscopic Su... XELOX Chemother... mFolfox6 chemot... Fast Track Peri... Conventional Pe... Open Surgery fo... | 18 Years - | Zhejiang University | |
| Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | NCT06302062 | Advanced Solid ... Tumor Associate... Immunotherapy | Tumor Associate... cyclophosphamid... IL-2 Serplulimab Inj... | 18 Years - 75 Years | Guangzhou FineImmune Biotechnology Co., LTD. | |
| Rheumatologic Adverse Events and Cancer Immunotherapy | NCT04791150 | Oncology Autoimmunity Arthritis Adverse Drug Ev... | Fill in a form | 18 Years - | Poitiers University Hospital | |
| Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | NCT06302062 | Advanced Solid ... Tumor Associate... Immunotherapy | Tumor Associate... cyclophosphamid... IL-2 Serplulimab Inj... | 18 Years - 75 Years | Guangzhou FineImmune Biotechnology Co., LTD. | |
| PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment | NCT02864030 | Metastatic Brea... Toxicity Neurotoxicity Drug Toxicity Adverse Drug Ev... | ERIBULIN MESYLA... | 18 Years - | Oncologia Medica dell'Ospedale Fatebenefratelli | |
| Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer | NCT05800054 | Esophageal Neop... Adverse Drug Ev... | Nutritional Sup... Docetaxel cisplatin Radiotherapy | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717699 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines. | NCT05266300 | Adverse Drug Ev... Colon Cancer Breast Cancer Pancreas Cancer Rectal Cancer Gastric Cancer Oesophageal Can... Bile Duct Cance... | DPYD genotype | 18 Years - | University of Southern Denmark | |
| Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717699 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717712 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia | NCT04770922 | Acute Lymphobla... Adverse Drug Ev... | - 21 Years | Cipherome, Inc. | ||
| A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) | NCT06120712 | Tumor Infiltrat... Safety Melanoma Efficacy Adverse Drug Ev... | GC101 TIL | 18 Years - 75 Years | Shanghai Juncell Therapeutics | |
| Rheumatologic Adverse Events and Cancer Immunotherapy | NCT04791150 | Oncology Autoimmunity Arthritis Adverse Drug Ev... | Fill in a form | 18 Years - | Poitiers University Hospital | |
| Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas | NCT04635956 | Chemotherapy Anti-pd-1 Antib... Cervical Neuroe... Adverse Drug Ev... Recurrent Cervi... Advanced Cervic... Objective Respo... | Drug therapy | 18 Years - | Peking Union Medical College Hospital | |
| Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients | NCT02324803 | Self Efficacy Adverse Drug Ev... Carcinoma, Rena... | pazopanib | 18 Years - | Southern China Urology Cancer Consortium | |
| Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer | NCT05800054 | Esophageal Neop... Adverse Drug Ev... | Nutritional Sup... Docetaxel cisplatin Radiotherapy | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors | NCT05417750 | Tumor Infiltrat... Safety Advanced Solid ... Immunotherapy Efficacy Adverse Drug Ev... | TIL therapy | 18 Years - 75 Years | Shanghai Juncell Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
